Savara Inc.
Savara Inc. (SVRA) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · SVRA · as of Jun 8, 2026
Key Statistics
Explore Savara Inc. Data
svra stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 11 · Buy rate: 81.8%
The SVRA analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month price target is $10.00, representing +95.12% upside from the current price of $5.13.
Competitors & Peers
svra competitorsSVRA
BCAX
EYPT
GERN
GHRS
KURAStock Performance
Full HistoryAbout Savara Inc.
Savara Inc. a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, …
what is savara inc. · svra stock overview · savara inc. company profile · who is savara inc. ceo · svra NASDAQ · savara inc. headquarters · savara inc. business segments
About Stock Overview & Key Data
Savara Inc. (SVRA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Apr 28, 2017. As of the latest trading session, SVRA stock price is $5.13, with a market capitalization of $1.1B. The stock has returned +115.47% over the past 12 months and -14.96% year-to-date.
According to 11 Wall Street analysts, the consensus rating for Savara Inc. stock is Buy, with an average 12-month price target of $10.00. In fiscal year 2025, Savara Inc. reported revenue of — and net income of -$118.8M. For detailed data — including Savara Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Savara Inc. (SVRA) stock price is $5.13. The stock is traded on NASDAQ under the ticker symbol SVRA. The 52-week range is $1.98 – $7.00.